The role of DARPP-32 in the actions of drugs of abuse (Q35908686)

11 August 2017

1 reference

title

The role of DARPP-32 in the actions of drugs of abuse (English)

1 reference

11 August 2017

Jean-Antoine Girault

5

0 references

Angus C. Nairn

object named as

Angus C Nairn

series ordinal

1

0 references

Paul Greengard

series ordinal

6

object named as

Paul Greengard

1 reference

11 August 2017

2

Per Svenningsson

1 reference

11 August 2017

Akinori Nishi

3

1 reference

11 August 2017

Gilberto Fisone

series ordinal

4

1 reference

11 August 2017

publication date

1 January 2004

1 reference

11 August 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Neuropharmacology

1 reference

11 August 2017

volume

47 Suppl 1

1 reference

11 August 2017

page(s)

14-23

1 reference

A gene expression atlas of the central nervous system based on bacterial artificial chromosomes

11 August 2017

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE02033

A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Distribution of DARPP-32 in the basal ganglia: an electron microscopic study

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Presynaptic nicotinic ACh receptors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Dopamine D(1) receptor-induced gene transcription is modulated by DARPP-32

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Immunohistochemical localization of DARPP-32 in striatal projection neurons and striatal interneurons: implications for the localization of D1-like dopamine receptors on different types of striatal neurons

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Molecular basis of long-term plasticity underlying addiction

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Nicotinic receptors in the development and modulation of CNS synapses.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Chronic morphine exposure and spontaneous withdrawal are associated with modifications of dopamine receptor and neuropeptide gene expression in the rat striatum

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Bidirectional regulation of DARPP-32 phosphorylation by dopamine.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Transcriptional attenuation following cAMP induction requires PP-1-mediated dephosphorylation of CREB.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

DARPP-32 knockout mice exhibit impaired reversal learning in a discriminated operant task.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

DARPP-32: an integrator of neurotransmission

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Spatiotemporal dynamics of CREB phosphorylation: transient versus sustained phosphorylation in the developing striatum

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Mechanism of regulation of casein kinase I activity by group I metabotropic glutamate receptors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

The DARPP-32 knockout mouse

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Dopamine- and cAMP-regulated phosphoprotein DARPP-32: phosphorylation of Ser-137 by casein kinase I inhibits dephosphorylation of Thr-34 by calcineurin

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

DARPP-32: regulator of the efficacy of dopaminergic neurotransmission

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Neuronal and behavioural abnormalities in striatal function in DARPP-32-mutant mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Differential expression of protein phosphatase 1 isoforms in mammalian brain.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Phosphorylation of DARPP-32, a Dopamine- and cAMP-regulated Phosphoprotein, by Casein Kinase Iin Vitroandin Vivo

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Mu- and delta-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Metabotropic glutamate receptor agonist increases neuropeptide mRNA expression in rat striatum

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

D(2) dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Distribution, biochemistry and function of striatal adenosine A2A receptors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Pharmacological agents acting at subtypes of metabotropic glutamate receptors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

D(1) dopamine receptor activation reduces GABA(A) receptor currents in neostriatal neurons through a PKA/DARPP-32/PP1 signaling cascade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Monosynaptic inhibition of neurons of the substantia nigra by caudato-nigral fibers

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

DARPP-32 and regulation of the ethanol sensitivity of NMDA receptors in the nucleus accumbens

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Amplification of dopaminergic signaling by a positive feedback loop

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Diverse psychotomimetics act through a common signaling pathway

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Dopamine receptor-interacting proteins: the Ca(2 ) connection in dopamine signaling.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Role of alpha7 nicotinic receptors in nicotine dependence and implications for psychiatric illness

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

A review of central 5-HT receptors and their function

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Blockade of D-2 dopamine receptors strongly enhances the potency of enkephalins to inhibit dopamine-sensitive adenylate cyclase in rat neostriatum: involvement of delta- and mu-opioid receptors.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Coordinated Expression of Dopamine Receptors in Neostriatal Medium Spiny Neurons

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

The neurobiology of slow synaptic transmission

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Metabotropic Glutamate Receptor Activation Produces Extrapyramidal Motor System Activation That Is Mediated by Striatal Dopamine

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Nicotine as a modulator of behavior: beyond the inverted U.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Reduction of cocaine place preference in mice lacking the protein phosphatase 1 inhibitors DARPP 32 or Inhibitor 1.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Ethanol inhibits NMDA-activated ion current in hippocampal neurons

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Addiction and the brain: The neurobiology of compulsion and its persistence

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

DARPP-32 mediates serotonergic neurotransmission in the forebrain

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Motivational effects of ethanol in DARPP-32 knock-out mice.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Striatal axons to the globus pallidus, entopeduncular nucleus and substantia nigra come mainly from separate cell populations in cat.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.NEUROPHARM.2004.05.010

Identifiers

DOI

10.1016/J.NEUROPHARM.2004.05.010

1 reference

11 August 2017

1 reference